|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Serum tumor markers in the management of ovarian, endometrial and cervical cancer显示文摘 | Angiolo Gadducci Stefania Cosio Angelo Carpi Andrea Nicolini Andrea Riccardo Genazzani | 2003 | Biomedicine & Pharmacotherapy2003，，1： | 2 |
| 2 | Bioactive calcium silicate ceramics and coatings显示文摘 | Liu Xuanyong Morra Marco Carpi Angelo Li Bao’e | 2008 | Biomedicine & Pharmacotherapy2008，62，8： | 1 |
| 3 | Role of Genetics in Azoospermia显示文摘 | Joo Yeon Lee Rima Dada Edmund Sabanegh Angelo Carpi | | 0，，： | 1 |
| 4 | Plasma matrix metalloproteinase-9 better predicts outcome than N-terminal protype-B natriuretic peptide in patients with systolic heart failure and a high prevalence of coronary artery disease显示文摘 | Frank Lloyd Dini Simona Buralli Gani Bajraktari Shpend Elezi Emiliano Duranti Maria Rita Metelli Angelo Carpi Stefano Taddei | 2009 | Biomedicine & Pharmacotherapy2009，，5： | 1 |
| 5 | Skin vasoreactivity to insulin iontophoresis is reduced in elderly subjects and is absent in treated non-insulin-dependent diabetes patients显示文摘 | Marco Rossi Adamasco Cupisti Roberto Ricco Gino Santoro Ferdinando Pentimone Angelo Carpi | 2004 | Biomedicine & Pharmacotherapy2004，，10： | 1 |
| 6 | Restaging after neoadjuvant chemoradiotherapy for rectal adenocarcinoma: role of F18-FDG PET显示文摘 | Carlo Capirci Domenico Rubello Franca Chierichetti Giorgio Crepaldi Angelo Carpi Andrea Nicolini Giovanni Mandoliti Cesare Polico | 2004 | Biomedicine & Pharmacotherapy2004，，： | 1 |
| 7 | Hemodynamic parameters regulating vascular inflammation and atherosclerosis: A brief update显示文摘 | Victoria Ridger Rob Krams Angelo Carpi Paul C. Evans | 2008 | Biomedicine & Pharmacotherapy2008，，8： | 1 |
| 8 | Minimally invasive radioguided parathyroidectomy显示文摘 | Domenico Rubello Sandro Giannini Chiara Martini Andrea Piotto Lucia Rampin Stefano Fanti Michela Armigliato Alfredo Nardi Angelo Carpi Giuliano Mariani Milton D. Gross Maria Rosa Pelizzo | 2006 | Biomedicine & Pharmacotherapy2006，，3： | 1 |
| 9 | Treatment of mild non-chemotherapy-induced iron deficiency anemia in cancer patients: Comparison between oral ferrous bisglycinate chelate and ferrous sulfate显示文摘 | Paola Ferrari Andrea Nicolini Maria Laura Manca Giuseppe Rossi Loretta Anselmi Massimo Conte Angelo Carpi Ferruccio Bonino | 2012 | Biomedicine & Pharmacotherapy2012，，6： | 1 |
| 10 | Serum tumor markers in the management of ovarian, endometrial and cervical cancer显示文摘 | Angiolo Gadducci Stefania Cosio Angelo Carpi Andrea Nicolini Andrea Riccardo Genazzani | 2003 | Biomedicine & Pharmacotherapy2003，，1： | 1 |
| 11 | Histological substrate of human atrial fibrillation显示文摘 | Cristina Chimenti Matteo A. Russo Angelo Carpi Andrea Frustaci | 2009 | Biomedicine & Pharmacotherapy2009，，3： | 1 |
| 12 | Final results of a 2:1 control-case observational study using interferon beta and interleukin-2,in addition to first-line hormone therapy,in estrogen receptor-positive,endocrine-responsive metastatic breast cancer patients显示文摘Aim:We conducted a pilot study that combines immunotherapy(cyclic interleukin-2 interferon-beta sequence)and hormone therapy(HT)to overcome endocrine resistance in metastatic breast cancer.Methods:The final results of a 2:1 control-case retrospective observational study are here shown following 22 additional months of postoperative follow-up and 6 further controls.There were 95 controls and 42 cases in total.The 95 controls were ER+/HER2-metastatic breast cancer patients who underwent first-line HT with aromatase inhibitors(AIs)or fulvestrant.Twenty-eight of them(28.9%)also received biological drugs including cyclin kinase inhibitors(CKIs).The 42 cases were ER+metastatic breast cancer patients who received interferon beta-interleukin-2 immunotherapy in addition to first-line HT.Selective estrogen receptor modulators/down-regulators(SERMs/SERDs)were used for HT in 39(92.9%)of them and AIs in the remaining 3.Results:Median progression-free survival(PFS)and overall survival(OS)were significantly longer in the 42 studied patients who received hormone immunotherapy(HIT)than in the 95 controls(median time 33 vs.18 months,P=0.002,and 81 vs.62 months,P=0.019).In the analysis adjusted for disease-free interval(DFI),hormone receptor,HER2 status,visceral involvement,AIs,and biological therapy,the PFS and OS hazard ratio(HR)further increased in favor of the 42 cases(P=0.004 and P=0.044 respectively).In the same ER+/HER2-metastatic breast cancer patients treated with both AIs and CKIs,a median PFS ranging from 25.3 to 28.18 months and a median OS of 37.5 months were observed.Conclusions:This study strongly suggests multi-center randomized clinical trials should be performed to enter our proposed immunotherapy into clinical practice. | Andrea Nicolini Giuseppe Rossi Paola Ferrari Riccardo Morganti Angelo Carpi | 2022 | Journal of Cancer Metastasis and Treatment2022，8，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员